Our pipeline of high-value
product opportunities
product opportunities
LIFE-001:
The ultimate pipeline-in-a-product
LIFE-001 is advancing for the treatment of multiple immune-mediated disorders and organ transplant rejection.
LIFE-001 is a structurally and mechanistically novel, organ-sparing, immunophilin-independent calcineurin activation inhibitor (CNai) delivered as a long-acting injectable, being developed for the prevention of organ transplant rejection. Unlike currently available calcineurin inhibitors such as cyclosporin, voclosporin, and tacrolimus, LIFE-001 does not depend on intermediary immunophilin chaperone proteins and directly targets and binds calcineurin to keep it inactive and prevent T-cell activation and proliferation.
LIFE-001 has demonstrated compelling efficacy in preclinical models and has shown substantially improved safety over legacy calcineurin inhibitors. LIFE-001 is currently being evaluated in a first-in-human Phase 1 clinical trial with kidney transplantation and islet cell transplantation studies expected to begin in early 2027.
Drug Discovery & Development Alliance with
LifeMine and GlaxoSmithKline (GSK) entered a drug discovery and development alliance, the first such agreement in genomic drug discovery from fungi, to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas.